Please assess the completion status of the following clinical trial:

Trial Title: Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically confirmed invasive breast cancer, stage I - IV, treated at Lyndon B. Johnson General Hospital in the Harris Health System.~2. Patients = or \> 18 years old and \< 75 years old.~3. Patients scheduled to undergo paclitaxel chemotherapy for breast cancer.~4. Patients with adequate renal function, as evidenced in laboratory values = or \< 3 months old: epidermal growth factor receptor (eGFR) = or \> 60 mL/min/1.73m2.~5. Patients with adequate hepatic function per institutional testing standards, as evidenced in laboratory values = or \< 3 months old: (1) The screening results for total bilirubin must be \< 1.5 times the upper limit of normal. (2) The screening results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be \< 2 times the upper limit of normal.~6. Patients who speak English and/or Spanish.~7. Patients who are willing and able to review, understand, and provide written consent.~8. Patients with an Eastern Cooperative Oncology performance status of 0 or 1.~Exclusion Criteria:~1. Patients with a history of or known diagnosis of diabetes according to national guidelines (fasting plasma glucose \> or = 126 mg/dL or random plasma glucose \> or = 200 mg/dL), as evidenced in laboratory values \< or = 3 months old).~2. Patients using carbonic anhydrase inhibitors (acetazolamide \[Diamox®\], brinzolamide \[Azopt®\], methazolamide \[Neptazane®\], dorzolamide \[Trusopt®\], pomegranate ellagitannins), cimetidine, or topiramate.~3. Patients who are enrolled in another symptom management trial.~4. Patients with nerve pathology or clinically identified neuropathy.~5. Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to the medication used in the study.~6. Patients with any condition associated with increased risk of metformin-associated lactic acidosis (e.g., congestive heart failure defined as New York Heart Association Class III or IV functional status, history of acidosis of any type).~7. Patients with intestinal issues, including malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.~8. Patients who are pregnant are excluded. Pre-menopausal women must have a negative pregnancy test. Patients that are post menopausal, or that have had a hysterectomy do not need to have a pregnancy test.~9. Patients with any condition that precludes use of the study medication as determined by the treating physician.~10. Patients with a diagnosis of hepatitis or HIV.~11. Patients currently receiving or scheduled to receive a chemotherapy infusion other than Adriamycin/Cyclophosphamide prior to initiation of the metformin adaptation phase are not eligible. Patients who are receiving Adriamycin/Cyclophosphamide must be scheduled to be at least 8 days post-chemotherapy infusion prior to initiation of the metformin adaptation phase in order to be eligible.~12. Patients who are currently using metformin (eg, Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Metformin Group (Type: EXPERIMENTAL): Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
- Placebo Group (Type: PLACEBO_COMPARATOR): Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).